CMS Grants Transitional Pass-Through Status for Gozellix

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Centers for ...
Business Insider

Teleflex Announces Publication of Early Patient Experience Data Highlighting the UroLift® System as a Superior Treatment to Rezum™ Steam Injection in Patients with Enlarged ...

Data Shows Minimally Invasive Treatment Provides Rapid Symptom Relief, Allowing Men to Return to Daily Activities Quickly WAYNE, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX ...
CURE

FDA Approves Bosaya and Aukelso Biosimilars for Solid Tumor Care

The FDA approved Bosaya and Aukelso, biosimilars of Prolia and Xgeva, respectively, for the treatment of solid tumors, like ...
The Manila Times

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® ...
icr.ac.uk

Funding injection into prostate cancer research

Prostate cancer researchers at The Institute of Cancer Research, London, are launching two new collaborations that will make use of cutting-edge genetic technology to help improve patients’ treatment ...
WWLP-22News

Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate ...

OXFORD, United Kingdom, May 1, 2025 /PRNewswire/ -- Blue Earth Therapeutics today announced further progress in development of its radiohybrid, lutetium-labelled, PSMA targeted, investigational ...